These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33336224)

  • 1. Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome.
    Rafii MS; Zaman S; Handen BL
    J Prev Alzheimers Dis; 2021; 8(1):48-51. PubMed ID: 33336224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further understanding the connection between Alzheimer's disease and Down syndrome.
    Snyder HM; Bain LJ; Brickman AM; Carrillo MC; Esbensen AJ; Espinosa JM; Fernandez F; Fortea J; Hartley SL; Head E; Hendrix J; Kishnani PS; Lai F; Lao P; Lemere C; Mobley W; Mufson EJ; Potter H; Zaman SH; Granholm AC; Rosas HD; Strydom A; Whitten MS; Rafii MS
    Alzheimers Dement; 2020 Jul; 16(7):1065-1077. PubMed ID: 32544310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease in people with Down's syndrome: the prospects for and the challenges of developing preventative treatments.
    Castro P; Zaman S; Holland A
    J Neurol; 2017 Apr; 264(4):804-813. PubMed ID: 27778163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomal biomarkers in Down syndrome and Alzheimer's disease.
    Hamlett ED; Ledreux A; Potter H; Chial HJ; Patterson D; Espinosa JM; Bettcher BM; Granholm AC
    Free Radic Biol Med; 2018 Jan; 114():110-121. PubMed ID: 28882786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age of Alzheimer's disease diagnosis in people with Down syndrome and associated factors: Results from the Horizon 21 European Down syndrome consortium.
    Larsen FK; Baksh RA; McGlinchey E; Langballe EM; Benejam B; Beresford-Webb J; McCarron M; Coppus A; Falquero S; Fortea J; Levin J; Loosli SV; Mark R; Rebillat AS; Zaman S; Strydom A
    Alzheimers Dement; 2024 May; 20(5):3270-3280. PubMed ID: 38506627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down Syndrome Biobank Consortium: A perspective.
    Aldecoa I; Barroeta I; Carroll SL; Fortea J; Gilmore A; Ginsberg SD; Guzman SJ; Hamlett ED; Head E; Perez SE; Potter H; Molina-Porcel L; Raha-Chowdhury R; Wisniewski T; Yong WH; Zaman S; Ghosh S; Mufson EJ; Granholm AC
    Alzheimers Dement; 2024 Mar; 20(3):2262-2272. PubMed ID: 38270275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease in Down syndrome: An overlooked population for prevention trials.
    Strydom A; Coppus A; Blesa R; Danek A; Fortea J; Hardy J; Levin J; Nuebling G; Rebillat AS; Ritchie C; van Duijn C; Zaman S; Zetterberg H
    Alzheimers Dement (N Y); 2018; 4():703-713. PubMed ID: 30581976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology.
    Handen BL; Lott IT; Christian BT; Schupf N; OBryant S; Mapstone M; Fagan AM; Lee JH; Tudorascu D; Wang MC; Head E; Klunk W; Ances B; Lai F; Zaman S; Krinsky-McHale S; Brickman AM; Rosas HD; Cohen A; Andrews H; Hartley S; Silverman W;
    Alzheimers Dement (Amst); 2020; 12(1):e12065. PubMed ID: 32775597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo quasi-elastic light scattering detects molecular changes in the lenses of adolescents with Down syndrome.
    Sarangi S; Minaeva O; Ledoux DM; Parsons DS; Moncaster JA; Black CA; Hollander J; Tripodis Y; Clark JI; Hunter DG; Goldstein LE
    Exp Eye Res; 2024 Apr; 241():109818. PubMed ID: 38422787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased plasma DYRK1A with aging may protect against neurodegenerative diseases.
    Delabar JM; Lagarde J; Fructuoso M; Mohammad A; Bottlaender M; Doran E; Lott I; Rivals I; Schmitt FA; Head E; Sarazin M; Potier MC
    Transl Psychiatry; 2023 Apr; 13(1):111. PubMed ID: 37015911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) study.
    Petersen ME; Zhang F; Schupf N; Krinsky-McHale SJ; Hall J; Mapstone M; Cheema A; Silverman W; Lott I; Rafii MS; Handen B; Klunk W; Head E; Christian B; Foroud T; Lai F; Rosas HD; Zaman S; Ances BM; Wang MC; Tycko B; Lee JH; O'Bryant S;
    Alzheimers Dement (Amst); 2020; 12(1):e12039. PubMed ID: 32626817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adults with Down syndrome in randomized clinical trials targeting prevention of Alzheimer's disease.
    Silverman W; Krinsky-McHale SJ; Zigman WB; Schupf N;
    Alzheimers Dement; 2022 Oct; 18(10):1736-1743. PubMed ID: 34873819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The AT(N) framework for Alzheimer's disease in adults with Down syndrome.
    Rafii MS; Ances BM; Schupf N; Krinsky-McHale SJ; Mapstone M; Silverman W; Lott I; Klunk W; Head E; Christian B; Lai F; Rosas HD; Zaman S; Petersen ME; Strydom A; Fortea J; Handen B; O'Bryant S
    Alzheimers Dement (Amst); 2020; 12(1):e12062. PubMed ID: 33134477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers show value of studying dementia in Down syndrome.
    Granholm AC; Ledreux A
    Nat Rev Neurol; 2021 Oct; 17(10):599-600. PubMed ID: 34465922
    [No Abstract]   [Full Text] [Related]  

  • 15. "Down syndrome: an insight of the disease".
    Asim A; Kumar A; Muthuswamy S; Jain S; Agarwal S
    J Biomed Sci; 2015 Jun; 22(1):41. PubMed ID: 26062604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probing the proteome to explore potential correlates of increased Alzheimer's-related cerebrovascular disease in adults with Down syndrome.
    Moni F; Petersen ME; Zhang F; Lao PJ; Zimmerman ME; Gu Y; Gutierrez J; Rizvi B; Laing KK; Igwe KC; Sathishkumar M; Keator D; Andrews H; Krinsky-McHale S; Head E; Lee JH; Lai F; Yassa MA; Rosas HD; Silverman W; Lott IT; Schupf N; O'Bryant S; Brickman AM
    Alzheimers Dement; 2022 Oct; 18(10):1744-1753. PubMed ID: 35212182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The National Institutes of Health INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project: Accelerating research discoveries for people with Down syndrome across the lifespan.
    Bardhan S; Li H; Tarver E; Schramm C; Brown M; Garcia L; Schwartz B; Mazzucco A; Natarajan N; Walsh E; Ryan L; Pearson G; Parisi MA
    Am J Med Genet C Semin Med Genet; 2024 Mar; 196(1):e32081. PubMed ID: 38197535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adapting prescribing criteria for amyloid-targeted antibodies for adults with Down syndrome.
    Hillerstrom H; Fisher R; Janicki MP; Chicoine B; Christian BT; Esbensen A; Esralew L; Fortea J; Hartley S; Hassenstab J; Keller SM; Krinsky-McHale S; Lai F; Levin J; McCarron M; McDade E; Rebillat AS; Rosas HD; Silverman W; Strydom A; Zaman SH; Zetterberg H
    Alzheimers Dement; 2024 May; 20(5):3649-3656. PubMed ID: 38480678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are biomarkers harmful to recruitment and retention in Alzheimer's disease clinical trials? An international perspective.
    Hampel H; Prvulovic D
    J Nutr Health Aging; 2012 Apr; 16(4):346-8. PubMed ID: 22499455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute Regression in Down Syndrome.
    Handen B; Clare I; Laymon C; Petersen M; Zaman S; O'Bryant S; Minhas D; Tudorascu D; Brown S; Christian B
    Brain Sci; 2021 Aug; 11(8):. PubMed ID: 34439728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.